Trulive Medical's Self-Developed PAFLASH® Pulmonary Thrombus Removal System Obtains NMPA Approval for Market Launch

On March 26, 2026, Trulive Medical's self-developed PAFLASH® Pulmonary Thrombus Removal System has recently obtained approval from the National Medical Products Administration (NMPA) (Registration No.: NMPA 20263030612) and been officially launched in the Chinese market.

On March 26, 2026, Trulive Medical's self-developed PAFLASH® Pulmonary Thrombus Removal System has recently obtained approval from the National Medical Products Administration (NMPA) (Registration No.: NMPA 20263030612) and been officially launched in the Chinese market.

Related Articles

You might also be interested in these

Trulive Completes New Round of Over 100 Million Yuan Series C Financing, Continuing to Strengthen Platform Layout in Cardiovascular Intervention

Trulive Completes New Round of Over 100 Million Yuan Series C Financing, Continuing to Strengthen Platform Layout in Cardiovascular Intervention

10/10/2026

Trulive Medical Launches NeoBlazar® Transcatheter Edge-to-Edge Repair System, Marking the New Domestic Era for Tricuspid Interventional Therapy

Trulive Medical Launches NeoBlazar® Transcatheter Edge-to-Edge Repair System, Marking the New Domestic Era for Tricuspid Interventional Therapy

7/22/2026

Double List Honors! Trulive Medical Named to Future Healthcare 100 List Again, Dual Rankings Demonstrate Solid Innovation Capabilities

Double List Honors! Trulive Medical Named to Future Healthcare 100 List Again, Dual Rankings Demonstrate Solid Innovation Capabilities

5/22/2026